Prognosis of METTL-14 in Endometrial Carcinoma

September 29, 2025 updated by: Monica Ashraf Alfy, Assiut University

Prognostic Impact of Immunohistochemical Expression of METTL-14 in Endometrial Carcinoma

  1. To evaluate immunohistochemical expression of METTL14 in type1 endometrial carcinoma.
  2. To evaluate the correlation between METTL14 expression and clinicopathological parameters of patients with type 1endometrial carcinoma such as tumor grade, lymhovascular invasion, age of pateints, tumor stage, presence of myometrial invasion and presence of cervical stroma affection.
  3. To assess correlation of METTL-14 expression with disease free survival and overall survival.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Endometrial cancer(EC) is the second most common gynecologic cancer worldwide(1). In Egypt its incidence rate has increased in recent years, reaching 4.1 per 100,000 women(2). The most common histological subtype is endometrioid adenocarcinoma(3). Endometrial carcinoma can be divided into:Type I and Type II tumors. The incidence of Type I is 60-80% and that of Type II is 20%(4).

N6-methyladenosine (m6A)is the most abundant RNA modification in mammalian mRNA and has a crucial role in the occurrence and development of various diseases, particularly malignant tumors(3). Many factors were found to affect the prognosis of endometrial carcinoma, one of these factors is m6A RNA methylation(5). This modification is dynamic and reversible, and it is catalyzed by three main types of regulators(3). It has been reported that m6A methylation was performed via methyltransferase complex regulators composed of "writer," "eraser," and "reader"(6).

Methyltransferase like 14 (METTL14), a member of "writer", acts to regulate the occurrence of various cancers(7). In most tumors METTL14 acts as an antioncogene, regulating the RNA of genes that help the cell detect and repair DNA damage, acting as a protective mechanism against cancer. Reducing m6A mRNA may be due to METTL14 mutation. Reducing m6A mRNA levels in endometrial cancer cells could enhance cell proliferation and tumorigenicity in vitro and in vivo(8).The role of METTL14 as a risk factor in prognosis of endometrial carcinoma is still unknown.

Study Type

Observational

Enrollment (Estimated)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Egypt
      • Asyut, Egypt
        • AssuitU

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

endometrial carcinoma

Description

Inclusion Criteria:

  • Cases of type1endometrial carcinoma with:

    1. Hystrectomy operation
    2. Available full clinical data about patient (age, complaint, findings in clinical examination).
    3. Full data about previous biopsy and radiology.
    4. Full data about patient survival, disease progression and history of chemotherapy for three years.

Exclusion Criteria:

  • 1. Any case of type 1 endometrial carcinoma with missing clinical, radiologic or follow up data.

    2. Cases with no available H&E stained slides or formalin fixed paraffin embedded block.

    3.D&C.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
endometrial carcinoma
Other: Observation
observation of METTL-14 prognosis
Behavioral: IHC
IHC of METTL-14

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluation of immunohistochemical Expression of METTL14 in Type 1 Endometrial Carcinoma
Time Frame: baseline

Measurement: Percentage of positive METTL14-stained tumor cells using immunohistochemistry (IHC).

Unit: Percentage (%).

Time Frame: Baseline.
baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 27, 2025

Primary Completion (Estimated)

August 1, 2026

Study Completion (Estimated)

October 1, 2026

Study Registration Dates

First Submitted

February 22, 2025

First Submitted That Met QC Criteria

March 3, 2025

First Posted (Actual)

March 6, 2025

Study Record Updates

Last Update Posted (Estimated)

September 30, 2025

Last Update Submitted That Met QC Criteria

September 29, 2025

Last Verified

September 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • prognosisendometrialcarcinoma

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Endometrial Cancer

Clinical Trials on Observation

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe